Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

Drugs, Aug 2011

KP Garnock-Jones, GM Keating, LJ Scott

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.2165%2F11596220-000000000-00000.pdf

Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

Correction Made Page 220, table IV, 'Concurrent studies' section, 'BCIRG 006' row: The cell entry in the 'Treatment regimen' column, which previously read: '' AC 60/600 mg/m2 q3w · 4 cycles - DOC 100 mg/m2 q3w · 4 cycles + concurrent TRA 6 mg/kg q1w · 12 cycles (8 mg/kg LD) - TRA 6 mg/kg q3w (total TRA treatment time of 1 y) DOC 75 mg/m2 + CAR AUC6 q3w · 6 cycles + concurrent TRA 6 mg/kg q1w · 18 cycles (8 mg/kg LD) - TRA 6 mg/kg q3w (total TRA treatment time of 1 y) AC 60/600 mg/m2 q3w · 4 cycles - DOC 100 mg/m2 q3w · 4 cycles'' has now been corrected as follows: '' AC 60/600 mg/m2 q3w · 4 cycles - DOC 100 mg/m2 q3w · 4 cycles + concurrent TRA 2 mg/kg q1w · 12 cycles (4 mg/kg LD) - TRA 6 mg/kg q3w (total TRA treatment time of 1 y) DOC 75 mg/m2 + CAR AUC6 q3w · 6 cycles + concurrent TRA 2 mg/kg q1w · 18 cycles (4 mg/kg LD) - TRA 6 mg/kg q3w (total TRA treatment time of 1 y) AC 60/600 mg/m2 q3w · 4 cycles - DOC 100 mg/m2 q3w · 4 cycles'' All online versions of this article have been updated to reflect this correction. - Note


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.2165%2F11596220-000000000-00000.pdf

KP Garnock-Jones, GM Keating, LJ Scott. Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, Drugs, 2011, 1578-1578, DOI: 10.2165/11596220-000000000-00000